The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis

Annals of Gastroenterology

Volumn 28, Issue 1, 2015, Pages 109-117

  Cholongitas, Evangelos ^a   Papatheodoridis, George V ^b   Goulis, John ^a   Vlachogiannakos, John ^b   Karatapanis, Stylianos ^c   Ketikoglou, John ^d   Vasiliadis, Themistoklis ^e   Kontos, George ^d   Karlaftis, Anastasios ^b   Akriviadis, Evangelos ^a  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c General Hospital of Rhodes   (Greece)

^d KAT HOSPITAL   (Greece)

^e AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

Decompensated cirrhosis; Entecavir; Nucleos(t)ide analogues; Tenofovir

Indexed keywords

ADEFOVIR; ENTECAVIR; LAMIVUDINE; PHOSPHATE; TENOFOVIR;

ADULT; ARTICLE; CHILD PUGH SCORE; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEPATITIS B; HUMAN; KIDNEY FUNCTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; OUTCOME ASSESSMENT; PHOSPHATE BLOOD LEVEL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURVIVAL;

EID: 84920393088     PISSN: 11087471     EISSN: 17927463     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Maddrey WC. Hepatitis B: an important public health issue. J Med Virol 2000;61:362-366.
2. Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol 2012;57:442-450.
3. EASL. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatology 2013;57:167-185.
4. Lv GC, Yao JM, Yang YD, et al. Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis. World J Gastroenterol 2013;19:3481-3486.
5. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B. Lancet Infect Dis 2008;8:167-178.
6. Papatheodoridis GV, Cholongitas E, Archimandritis AJ, Burroughs AK. Current management of hepatitis B virus infection before and after liver transplantation. Liver Int 2009;29:1294-1305.
7. Gara N, Zhao X, Collins MT, et al. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther 2012;35:1317-1325.
8. Ha NB, Ha NB, Garcia RT, et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009;50:727-734.
9. Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011;53:62-72.
10. Dauchy FA, Lawson-Ayayi S, de La FR, et al. Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy. Kidney Int 2011;80:302-309.
11. Flandre P, Pugliese P, Cuzin L, et al. Risk factors of chronic kidney disease in HIV-infected patients. Clin J Am Soc Nephrol 2011;6:1700-1707.
12. Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000;31:207-210.
13. Kapoor D, Guptan RC, Wakil SM, et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 2000;33:308-312.
14. Fontana RJ, Keeffe EB, Carey W, et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 2002;8:433-439.
15. Manolakopoulos S, Karatapanis S, Elefsiniotis J, et al. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. Am J Gastroenterol 2004;99:57-63.
16. Fontana RJ, Hann HW, Perrillo RP, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002;123:719-727.
17. Zoulim F, Radenne S, Ducerf C. Management of patients with decompensated hepatitis B virus association cirrhosis. Liver Transpl 2008;14(Suppl 2):S1-S7.
18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999;130:461-470.
19. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-649.
20. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-96.
21. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-843.
22. Koklu S, Tuna Y, Gulsen MT, et al. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. Clin Gastroenterol Hepatol 2013;11:88-94.
23. Murray KF, Carithers RL, Jr. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology 2005;41:1407-1432.
24. Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010;52:176-182.
25. Hyun JJ, Seo YS, Yoon E, et al. Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis. Liver Int 2012;32:656-664.
26. Lian JS, Zeng LY, Chen JY, et al. De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis. World J Gastroenterol 2013;19:6278-6283.